AnaptysBio, Inc. (NASDAQ:ANAB) Shares Bought by Barclays PLC

Barclays PLC lifted its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 117.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 44,300 shares of the biotechnology company’s stock after purchasing an additional 23,926 shares during the period. Barclays PLC owned 0.15% of AnaptysBio worth $1,486,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in ANAB. XTX Topco Ltd lifted its position in AnaptysBio by 49.1% during the third quarter. XTX Topco Ltd now owns 20,286 shares of the biotechnology company’s stock worth $680,000 after buying an additional 6,683 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of AnaptysBio by 4.8% in the 3rd quarter. Wellington Management Group LLP now owns 65,939 shares of the biotechnology company’s stock worth $2,209,000 after acquiring an additional 3,048 shares during the last quarter. Point72 DIFC Ltd raised its holdings in shares of AnaptysBio by 680.5% during the 3rd quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock worth $205,000 after acquiring an additional 5,342 shares during the period. Point72 Asset Management L.P. boosted its position in shares of AnaptysBio by 202.8% during the 3rd quarter. Point72 Asset Management L.P. now owns 54,200 shares of the biotechnology company’s stock valued at $1,816,000 after acquiring an additional 36,300 shares during the last quarter. Finally, Janus Henderson Group PLC purchased a new stake in shares of AnaptysBio in the third quarter valued at about $250,000.

AnaptysBio Trading Down 5.1 %

ANAB opened at $13.04 on Friday. The stock’s 50-day moving average price is $21.79 and its 200 day moving average price is $28.83. AnaptysBio, Inc. has a 12-month low of $13.00 and a 12-month high of $41.31. The firm has a market cap of $396.79 million, a price-to-earnings ratio of -2.14 and a beta of -0.11.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.72) by $0.58. The business had revenue of $30.02 million for the quarter, compared to analysts’ expectations of $7.92 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. On average, research analysts forecast that AnaptysBio, Inc. will post -6.02 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ANAB shares. JPMorgan Chase & Co. reduced their target price on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a research note on Thursday, December 19th. UBS Group upped their price objective on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Guggenheim cut their target price on AnaptysBio from $90.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, December 12th. BTIG Research downgraded AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd. Finally, Wedbush reiterated an “outperform” rating and set a $40.00 price target (down from $42.00) on shares of AnaptysBio in a report on Wednesday, December 11th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, AnaptysBio has an average rating of “Moderate Buy” and a consensus target price of $41.45.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.